In a potentially significant development in cardiac care using the ECG test, Southlake medtech HeartSciences has been granted a patent by the US Patent and Trademark Office for “ECG Measurement of Echocardiographic Measures of Diastolic Function of the Heart” using AI technology.
Cardiac testing laboratories – which operate as cardiac sciences – focus on applying artificial intelligence-based technology in electrocardiograms (also known as EKGs) to greatly expand and improve the clinical utility of ECGs by detecting cardiac dysfunction, which has been recognized as one of the earliest signs of heart disease. the heart. Usually, its onset occurs when the patient is still asymptomatic, the company says..
HeartSciences’ first device, the MyoVista Wavelet ECG, takes advantage of artificial intelligence machine learning to detect cardiac dysfunction that cannot be diagnosed by current conventional ECG. The company said its first algorithm is designed to provide diagnostic information regarding impaired cardiac relaxation associated with diastolic dysfunction in addition to all conventional ECG information — all in a single test.
The Quick Test can be performed in a wide range of settings
“ECG is a widespread, relatively low-cost, simple, rapid test that can be performed in a wide range of clinical settings by a non-specialist or clinical assistant physician. One of the most important needs in healthcare is the ability to Detecting heart failure early.” Adding diagnostic information related to heart dysfunction to the ECG will not only make it a more valuable tool for heart screening, but it also addresses a significant unmet need in the market with an estimated 100 million ECG tests performed annually in the The United States alone. “
An important indicator of heart health in general
Diastolic dysfunction is a problem with diastole, which is the first part of a person’s heartbeat. This occurs when the heart’s lower chambers do not relax as they should and, over time, can lead to diastolic heart failure. It is an important indicator of overall heart health because it impairs all common pathological processes of heart disease and is a sensitive indicator of cardiovascular impairment. The company said.
Currently, the diastolic function of the heart must be evaluated in a specialized cardiology setting, most commonly by echocardiography-based imaging. The ECG has had a limited, if any, role in assessing cardiac impairment, and thus the ability to assess diastolic heart function using ECG would make it a more valuable cardiac screening tool. Especially in frontline or point-of-care clinical settings, the company said.
A new era of ECG
“A growing body of published ECG research shows that ECG can have much greater clinical value, and this patent award reinforces our belief that HeartSciences is at the fore in what is expected to be a new era of ECG,” Simpson said. “This latest patent is an important extension of our intellectual property portfolio – providing significant future value to the company.”
Chief Operating Officer Mark Hills said the company is intent on protecting its patent rights.
“We are committed to patenting and protecting intellectual property related to our research and development efforts focused on expanding the clinical capabilities of ECG. We believe that patent and intellectual property protection is essential, with the pursuit of new developments in ECG, and we are proud to have been awarded this valuable patent by the Office of the States United States Patent and Trademark Office.
eighth US patent to date; Subscription closed in June
This is the company’s eighth US patent to date, bringing the total of patents granted to the company, including international, to 18. HeartSciences said it has also received permitting other applications by the European Patent Office and Israel with several additional patent applications pending in Several international jurisdictions including Brazil, Canada, India, South Korea, Mexico and the United Arab Emirates.
In June, the company closed on a public offering of $4.25 per share with total revenue of approximately $6.375 million.
At the time, HeartSciences said it expected to use the net proceeds from the show primarily to fund the FDA’s clearance of MyoVista, including the completion of a pivotal clinical validation study, and for the company’s general and working capital purposes.
Founded in 2008
HeartSciences was founded in 2008 with the goal of providing accurate and affordable screening tools for the early detection of heart disease through the continuous development of innovative electrocardiograms.
Heart disease, known as the “silent killer,” is a leading cause of death globally. Most patients with heart disease are unaware and do not develop symptoms. Identification of these asymptomatic patients remains a major challenge in health care.
According to the Centers for Disease Control, nearly 697,000 people in the United States died of heart disease in 2020, which is 1 in 5 deaths. The CDC said heart disease cost the United States about $229 billion each year from 2017 to 2018, including the cost of health care services, medications, and productivity lost through death.
Get the list.
Dallas innovates, every day.
Sign up to keep an eye on what’s new and next in Dallas-Fort Worth, every day.